Carisma Therapeutics
Carisma Therapeutics
CARM
NASDAQ
0.43
USD
2.38%
About
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors.
Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2.
CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 129.1K |
| Three Month Average Volume | 17.0M |
| High Low | |
| Fifty-Two Week High | 6.975 USD |
| Fifty-Two Week Low | 0.8 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 07 Aug 2024 |
| Price and Volume | |
| Current Price | 1.07 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.87% |
| Thirteen Week Relative Price Change | -24.83% |
| Twenty-Six Week Relative Price Change | -62.43% |
| Fifty-Two Week Relative Price Change | -87.66% |
| Year-to-Date Relative Price Change | -69.16% |
| Price Change | |
| One Day Price Change | -1.83% |
| Thirteen Week Price Change | -19.55% |
| Twenty-Six Week Price Change | -58.69% |
| Five Day Price Change | -5.31% |
| Fifty-Two Week Price Change | -84.54% |
| Year-to-Date Price Change | -63.48% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.65334 USD |
| Book Value Per Share (Most Recent Quarter) | 0.00867 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.65334 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.00867 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.77925 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.44502 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.50749 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.59153 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.78143 USD |
| Normalized (Last Fiscal Year) | -2.59153 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.59153 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.78143 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.59153 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.78143 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.91099 USD |
| Cash Per Share (Most Recent Quarter) | 0.97153 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.50691 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.69415 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.87494 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -210 |
| Cash Flow Revenue (Trailing Twelve Months) | -369 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -351.03% |
| Pretax Margin (Last Fiscal Year) | -582.34% |
| Pretax Margin (5 Year) | -267.21% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -594.75% |
| Operating Margin (Trailing Twelve Months) | -366.85% |
| Operating Margin (5 Year) | -272.66% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -582.34% |
| Net Profit Margin (Trailing Twelve Months) | -350.08% |
| Net Profit Margin (5 Year) | -255.66% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -43.57% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 158.34% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -55.75% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 9.91% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 255.27% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 45.58% |
| EPS Change (Trailing Twelve Months) | -57.12% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 123 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -38,577,000 |
| Net Debt (Last Fiscal Year) | -76,733,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 1 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 1 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 123 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 139 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -82,309,000 |
| Free Cash Flow (Trailing Twelve Months) | -76,514,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 3 |
| Total Debt to Equity (Most Recent Quarter) | 496 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -62.34% |
| Return on Assets (Trailing Twelve Months) | -75.38% |
| Return on Assets (5 Year) | -30.87% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -94.06% |
| Return on Equity (Trailing Twelve Months) | -216.21% |
| Return on Equity (5 Year) | -72.00% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -74.95% |
| Return on Investment (Trailing Twelve Months) | -91.33% |
| Return on Investment (5 Year) | -34.47% |